To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls
School of Medical Sciences, Örebro University, Örebro, Sweden.
Örebro University Hospital. Örebro University, School of Medical Sciences. Division of Gastroenterology, Department of Medicine, Örebro University Hospital, Örebro, Sweden.
Örebro University, School of Medical Sciences. Division of Gastroenterology, Department of Medicine, Örebro University Hospital, Örebro, Sweden.
Linköping University, Linköping, Sweden.
Show others and affiliations
2021 (English)In: Frontiers in Medicine, E-ISSN 2296-858X, Vol. 8, article id 727412Article in journal (Refereed) Published
Abstract [en]

Introduction: Microscopic colitis (MC) is an inflammatory bowel condition with two subtypes, lymphocytic colitis (LC) and collagenous colitis (CC). Unlike patients with ulcerative colitis (UC) and non-inflamed individuals, MC patients have reduced risk of developing colorectal cancer, possibly due to increased immune surveillance in MC patients.

Aim: To examine differences in levels of immunomodulatory molecules, including those involved in immune checkpoint mechanisms, in sera from patients with MC and in colonic biopsies from patients with MC and UC compared with controls.

Methods: Using Luminex, 23 analytes (4-1BB, 4-1BBL, APRIL, BAFF, BTLA, CD27, CD28, CD80, CTLA-4, E-cadherin, Galectin-3, GITR, HVEM, IDO, IL-2Rα, LAG-3, MICA, MICB, PD-1, PD-L1, PD-L2, sCD40L and TIM-3) were studied in serum from patients with active MC (n = 35) and controls (n = 23), and in colonic biopsies from patients with active LC (n = 9), active CC (n = 16) and MC in histological remission (LC n = 6, CC n = 6), active UC (n = 15) and UC in remission (n = 12) and controls (n = 58).

Results: In serum, IDO, PD-1, TIM-3, 4-1BB, CD27, and CD80 were decreased whereas 4-1BBL and IL-2Rα were increased in MC patients compared with controls. In contrast, in biopsies, levels of PD-L2 and 4-1BB were increased in MC and UC patients with active disease. Furthermore, in biopsies from CC and UC but not LC patients with active disease, CTLA-4, PD-1, APRIL, BAFF, and IL-2Rα were increased compared with controls. PD-L1 was increased in CC but not UC or LC patients. CD27 and TIM-3 were decreased in biopsies from MC patients in comparison to controls whereas levels of MICB were decreased in patients with active UC compared with controls.

Conclusions: Compared with non-inflamed controls, levels of soluble and membrane-bound immunomodulatory molecules were systemically and locally altered in MC and UC patients, with most analytes being decreased in serum but enhanced in colonic biopsies. These findings contribute to knowledge about checkpoint molecules and their role as biomarkers in MC and may also contribute to knowledge about possible mechanisms behind the seemingly protective effects of MC against colorectal cancer.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2021. Vol. 8, article id 727412
Keywords [en]
Colonic biopsies, colorectal cancer, immune checkpoints, immune surveillance, microscopic colitis, serum, ulcerative colitis
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-95302DOI: 10.3389/fmed.2021.727412ISI: 000715085000001PubMedID: 34722568Scopus ID: 2-s2.0-85118304770OAI: oai:DiVA.org:oru-95302DiVA, id: diva2:1608297
Note

Funding agencies:

Faculty of Medicine and Health, Örebro University

Örebro University Hospital Research Foundation OLL 926161 OLL-960784

Correction: Frontiers in Medicine. Vol. 11, 1506094

DOI: 10.3389/fmed.2024.1506094

WOS: 001363905600001

ScopusID: 2-s2.0-85210161783

Available from: 2021-11-03 Created: 2021-11-03 Last updated: 2024-12-06Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Bohr, JohanWickbom, AnnaHultgren, OlofWirén, AndersHultgren Hörnquist, Elisabeth

Search in DiVA

By author/editor
Bohr, JohanWickbom, AnnaHultgren, OlofWirén, AndersHultgren Hörnquist, Elisabeth
By organisation
Örebro University HospitalSchool of Medical Sciences
In the same journal
Frontiers in Medicine
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 67 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf